OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi ‘Atalante 1’ in Non-Small Cell Lung Cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
NANTES, France, July 28, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that Step-1 results of its Phase 3 clinical trial of
investigational product Tedopi, called Atalante 1, in HLA-A2 positive non-small cell lung cancer (NSCLC) patients after failure from immune checkpoint inhibitors (PD-1/PD-L1) will be presented in
an Oral Presentation at the ESMO Virtual Congress 2020, to be held on September 19 – 21, 2020.
Details of the presentation | |
Title: | Activity of Tedopi(OSE-2101) in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step1 results of Phase 3 ATALANTE-1 randomised trial |
Presentation: | #1260MO |
Session title: | Mini Oral presentation – NSCLC, Metastatic |
Available online from: September 18, 2020 |
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company
has several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Its
first-in-class clinical and preclinical portfolio has a diversified risk profile:
-
Tedopi (innovative combination of neoepitopes) : the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in
Non-Small Cell Lung Cancer post checkpoint inhibitor failure; due to Covid-19, voluntary definitive stop of new patient accrual in the Step-2 initially planned in the
trial.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in combination with checkpoint inhibitor Opdivo. - BI 765063 (OSE-172, anti-SIRPα monoclonal antibody): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.
- FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; Phase 2-ready asset in autoimmune diseases or in transplantation.
- OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in 2020.
- BiCKI: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity. Additional innovative research programs.
- CoVepiT: a prophylactic vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes. First preclinical results expected Q3 2020, possible clinical trial start by year end.
Lesen Sie auch
Due to the COVID-19 crisis, accrual of new patients in the clinical trial TEDOPaM is temporarily suspended and initiation timelines for both Phase 2 trials of OSE-127 could be impacted during the coming months.